Avanos Medical, Inc. (AVNS) analyst actions
Rating and price-target actions on AVNS in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the AVNS overview →
1 measured AVNS analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| CMS Maintains NOPAIN Act Eligibility for ON-Q* and AmbIT* Infusion Pumps; Adds Game Ready* in 2026 | Press release | +0.67% | -0.07% |
Keep exploring
More AVNS: earnings → · SEC filings → · AVNS overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| NOVUS THERAPEUTICS (NVUS) | 263 | -0.14% | 40% |
| Haemonetics Corporation (HAE) | 261 | -0.07% | 44% |
| Enanta Pharmaceuticals, Inc. (ENTA) | 257 | +0.06% | 50% |
| FORTY SEVEN (FTSV) | 257 | +0.01% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.